Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SH1573 |
Synonyms | |
Therapy Description |
SH1573 inhibits mutant forms of IDH2, potentially resulting in increased tumor cell differentiation (PMID: 34221866). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SH1573 | SH 1573|SH-1573 | IDH2 Inhibitor 5 | SH1573 inhibits mutant forms of IDH2, potentially resulting in increased tumor cell differentiation (PMID: 34221866). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH2 R140Q | hematologic cancer | predicted - sensitive | SH1573 | Preclinical - Cell culture | Actionable | In a preclinical study, SH1573 treatment decreased 2-HG levels and increased differentiation of a tumor cell line expressing IDH2 R140Q in culture (PMID: 34221866). | 34221866 |
IDH2 R172K | hematologic cancer | predicted - sensitive | SH1573 | Preclinical - Biochemical | Actionable | In a preclinical study, SH1573 inhibited the activity of IDH2 R172K in an in vitro assay (PMID: 34221866). | 34221866 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|